Objective: to analyze the role of Riven in the study of diseases. Methods: the research object is hepatitis B in our hospital. The study period is from October 2019 to February 2021. The number of cases studied was 70...Objective: to analyze the role of Riven in the study of diseases. Methods: the research object is hepatitis B in our hospital. The study period is from October 2019 to February 2021. The number of cases studied was 70. The research method is divided into groups according to the computer blind selection method, and half of the patients are treated with basic hospital treatment as the control group. Half of the patients were treated with Riven as the observation group. The fundamental purpose of the study is to compare the effects of the two treatments. Results: compared with the control group, there were significant differences (P 0.05). Conclusion: the treatment of hepatitis B with Riven can produce obvious signs of improvement and has unique advantages in clinical treatment, so it is worthy of promotion and adoption.展开更多
Objective: to explore the clinical treatment effect of suppurative tonsillitis. Methods: 60 patients diagnosed with suppurative tonsillitis admitted to our hospital from June 2020 to June 2021 were randomly divided in...Objective: to explore the clinical treatment effect of suppurative tonsillitis. Methods: 60 patients diagnosed with suppurative tonsillitis admitted to our hospital from June 2020 to June 2021 were randomly divided into the observation group and the control group, 30 in the observation group and 30 in the control group. Both groups used clinical medication, the control group was mainly potassium amoxicillin clavulanate, and the observation group was mainly oral moxifloxacin. On this basis, both groups added lotus Qingwen particles to compare the clinical efficacy. Results: Of 30 patients in the observation group, 23 were effective, 6 were ineffective and 96. 67%;compared with 30,14 were effective, 9 were ineffective and 76. 67% effective. average fever (3. 23 ± 1. 01) days, average anti-inflammatory (5. 01 ± 1. 21) days, cough (6. 24 ± 1. 34) per day;fever (1. 21 ± 0. 21) days, average (3. 12 ± 1. 01) days, average cough (2. 21 ± 0. 24) per day. One case in the observed group had obvious gastrointestinal reactions, accounting for 3. 33%. Four patients in the control group had significant gastrointestinal reactions, and three patients had mild vertigo, with a total of 23. 33% of the adverse reaction clinical symptoms. All the above data were P <0. 05. Conclusion: moxifloxacin has obvious efficacy and clinical value.展开更多
文摘Objective: to analyze the role of Riven in the study of diseases. Methods: the research object is hepatitis B in our hospital. The study period is from October 2019 to February 2021. The number of cases studied was 70. The research method is divided into groups according to the computer blind selection method, and half of the patients are treated with basic hospital treatment as the control group. Half of the patients were treated with Riven as the observation group. The fundamental purpose of the study is to compare the effects of the two treatments. Results: compared with the control group, there were significant differences (P 0.05). Conclusion: the treatment of hepatitis B with Riven can produce obvious signs of improvement and has unique advantages in clinical treatment, so it is worthy of promotion and adoption.
文摘Objective: to explore the clinical treatment effect of suppurative tonsillitis. Methods: 60 patients diagnosed with suppurative tonsillitis admitted to our hospital from June 2020 to June 2021 were randomly divided into the observation group and the control group, 30 in the observation group and 30 in the control group. Both groups used clinical medication, the control group was mainly potassium amoxicillin clavulanate, and the observation group was mainly oral moxifloxacin. On this basis, both groups added lotus Qingwen particles to compare the clinical efficacy. Results: Of 30 patients in the observation group, 23 were effective, 6 were ineffective and 96. 67%;compared with 30,14 were effective, 9 were ineffective and 76. 67% effective. average fever (3. 23 ± 1. 01) days, average anti-inflammatory (5. 01 ± 1. 21) days, cough (6. 24 ± 1. 34) per day;fever (1. 21 ± 0. 21) days, average (3. 12 ± 1. 01) days, average cough (2. 21 ± 0. 24) per day. One case in the observed group had obvious gastrointestinal reactions, accounting for 3. 33%. Four patients in the control group had significant gastrointestinal reactions, and three patients had mild vertigo, with a total of 23. 33% of the adverse reaction clinical symptoms. All the above data were P <0. 05. Conclusion: moxifloxacin has obvious efficacy and clinical value.
